目的 探讨血塞通联合尼莫地平对急性脑梗死患者认知功能的影响。方法 选取2013年3月—2018年3月在汉中市人民医院就诊的急性脑梗死患者105例，随机分为观察组（n=53）和对照组（n=52）。对照组在基础治疗基础上给予患者口服尼莫地平片30 mg，3次/d。观察组在对照组基础上将注射用血塞通400 mg加入500 mL 0.9%氯化钠注射液中静脉滴注，1次/d。均治疗14 d。对比两组简易精神状态检查量表（MMSE）评分、蒙特利尔认知功能评估量表（MoCA）评分、美国国立卫生研究院卒中量表（NIHSS）评分和Barthel指数（BI）评分及不良反应发生情况。结果 与对照组总有效率61.54%比较，观察组总有效率88.68%显著升高，差异有统计学意义（P<0.05）。治疗后两组MoCA评分和MMSE评分与治疗前比较均不同程度升高，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组MoCA评分和MMSE评分升高更为明显，组间差异有统计学意义（P<0.05）。治疗后两组NIHSS评分明显降低，BI评分明显升高，同组治疗前后比较差异均具有统计学意义（P<0.05）；且观察组NIHSS评分降低更为显著，BI评分升高更为显著，组间差异有统计学意义（P<0.05）。两组不良反应发生率比较差异无统计学意义。结论 血塞通联合尼莫地平可有效改善急性脑梗死患者的认知功能，值得临床推广。

Objective To investigate the effect of Xuesaitong combined with nimodipine on cognitive function in patients with acute cerebral infarction. Methods 105 patients with acute cerebral infarction in our hospital from March 2013 to March 2018 were randomly divided into the observation group (Xuesaitong + nimodipine, n=53) and the control group (nimodipine, n=52). The MMSE score, MoCA score, NIHSS score, Barthel index score and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). After treatment, the MoCA scores and MMSE scores in the two groups were significantly higher than those before treatment (P<0.05), and the increase in the MoCA score and the MMSE score in the observation group was more obvious (P<0.05). After treatment, the difference of NIHSS score and BI score between the two groups was statistically significant (P<0.05), and the decrease of NIHSS score in the observation group was more significant (P<0.05), and the increase of BI score was more significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Xuesaitong combined with nimodipine can effectively improve the cognitive function of patients with acute cerebral infarction, and is worthy of clinical promotion.